Indeed, recent studies have reported on the roles of bone marrow-derived stromal cells in protecting myeloproliferative neoplasms or acute myeloid leukaemia from the effects of JAK2 or FLT3 tyrosine kinase inhibitors, respectively (Manshouri et al, 2011; Parmar et al, 2011). Here, JAK2 is linked to myeloproliferative neoplasm.